Diagnostics firm Scanogen secured a $2.9 million grant from the U.S. National Institute of Allergy and Infectious Diseases to advance development of a culture-free, rapid test for bloodstream yeast infections. The automated, cartridge-based assay employs signal bead technology for direct detection of pathogens including Candida auris, aiming to provide results within two hours. The funding will accelerate reagent production scale-up, software integration, and preparation for pivotal clinical studies supportive of FDA clearance.